Journal Article
. 2011 Jan; 29(8):1014-21.
doi: 10.1200/JCO.2009.27.6543.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012

Georgiana K Ellis 1 William E Barlow  Julie R Gralow  Gabriel N Hortobagyi  Christy A Russell  Melanie E Royce  Edith A Perez  Danika Lew  Robert B Livingston  
Affiliations
  • PMID: 21220618
  •     17 References
  •     30 citations

Abstract

Purpose: Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm). All patients had subsequent weekly paclitaxel for 12 weeks before surgery.

Patients And Methods: Patients (n = 372) were randomly assigned to the standard arm (n = 186) or the continuous arm (n = 186) stratified by disease type (LABC, n = 256; IBC, n = 116). The primary outcome was microscopic pathologic complete response (pCR) at surgery. Secondary outcomes included disease-free survival, overall survival, and toxicity.

Results: More patients in the standard arm had grade 3 to 4 leukopenia and neutropenia, but there were more instances of stomatitis/pharyngitis and hand-foot skin reaction in the continuous arm. Assessed among 356 eligible patients, pCR was not different between the treatment groups stratified by disease type (P = .42). In subset analysis, higher pCR rates were observed in the continuous arm versus the standard arm only for stage IIIB disease (P = .0057) and in IBC (P = .06). Comparison of overall survival and disease-free survival showed no difference between treatment groups (P = .37 and P = .87, respectively).

Conclusion: No significant clinical benefit was seen for the investigational arm in this trial overall.

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Shan Man, Guido Bocci, +7 authors, Robert S Kerbel.
Cancer Res, 2002 May 23; 62(10). PMID: 12019144
Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
Georgiana K Ellis, Robert B Livingston, +2 authors, Tove Thompson.
J Clin Oncol, 2002 Aug 31; 20(17). PMID: 12202664
The importance of dose intensity in chemotherapy of metastatic breast cancer.
W Hryniuk, H Bush.
J Clin Oncol, 1984 Nov 01; 2(11). PMID: 6387060
Highly Cited. Review.
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin, Tadeusz Pienkowski, +30 authors, Breast Cancer International Research Group 001 Investigators.
N Engl J Med, 2005 Jun 03; 352(22). PMID: 15930421
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Marjorie C Green, Aman U Buzdar, +16 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2005 Aug 10; 23(25). PMID: 16087943
Inflammatory breast cancer: a review.
I A Jaiyesimi, A U Buzdar, G Hortobagyi.
J Clin Oncol, 1992 Jun 01; 10(6). PMID: 1588366
Review.
Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer.
W M Hryniuk, M N Levine, L Levin.
NCI Monogr, 1986 Jan 01; (1). PMID: 3534595
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
Gunter von Minckwitz, Günter Raab, +11 authors, Manfred Kaufmann.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837982
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
M Cristofanilli, A U Buzdar, +14 authors, G N Hortobagyi.
Cancer, 2001 Dec 18; 92(7). PMID: 11745249
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Georgiana K Ellis, William E Barlow, +6 authors, Robert B Livingston.
J Clin Oncol, 2011 Jan 12; 29(8). PMID: 21220618    Free PMC article.
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells.
Takeshi Natori, Masataka Sata, +3 authors, Masatoshi Makuuchi.
Biochem Biophys Res Commun, 2002 Oct 03; 297(4). PMID: 12359263
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Michael R Mancuso, Rachel Davis, +10 authors, Donald M McDonald.
J Clin Invest, 2006 Oct 04; 116(10). PMID: 17016557    Free PMC article.
Highly Cited.
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
C G Kleer, K L van Golen, S D Merajver.
Breast Cancer Res, 2001 Mar 16; 2(6). PMID: 11250736    Free PMC article.
Review.
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
W Hryniuk, M N Levine.
J Clin Oncol, 1986 Aug 01; 4(8). PMID: 3525765
Highly Cited.
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Vered Stearns, Baljit Singh, +9 authors, Daniel F Hayes.
Clin Cancer Res, 2003 Jan 23; 9(1). PMID: 12538460
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Taxanes in breast cancer: an update.
Alison K Conlin, Andrew D Seidman.
Curr Oncol Rep, 2006 Dec 14; 9(1). PMID: 17164044
Review.
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Jason A Zell, Walter Y Tsang, +2 authors, Hoda Anton-Culver.
Breast Cancer Res, 2009 Feb 21; 11(1). PMID: 19228416    Free PMC article.
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Robert Wesolowski, David Peereboom, +2 authors, George Thomas Budd.
Invest New Drugs, 2009 May 13; 28(4). PMID: 19434371
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Jennifer M Specht, Brenda F Kurland, +9 authors, David A Mankoff.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460489    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.
Konstantinos Papadimitriou, Konstantinos Papademetriou, Alexandros Ardavanis, Panteleimon Kountourakis.
J Thorac Dis, 2010 Sep 01; 2(3). PMID: 22263038    Free PMC article.
In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene.
Brandon T Nokes, Heather E Cunliffe, +4 authors, Julie E Lang.
J Cancer, 2013 Feb 07; 4(2). PMID: 23386909    Free PMC article.
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
Simon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil.
J Oncol, 2013 Sep 13; 2013. PMID: 24027583    Free PMC article.
Review.
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
A Sánchez-Muñoz, Y Plata-Fernández, +7 authors, P Sánchez-Rovira.
Clin Transl Oncol, 2013 Oct 03; 16(6). PMID: 24085576
Comparison of survival outcomes among cancer patients treated in and out of clinical trials.
Joseph M Unger, William E Barlow, +4 authors, Dawn L Hershman.
J Natl Cancer Inst, 2014 Mar 15; 106(3). PMID: 24627276    Free PMC article.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?
V Mandilaras, N Bouganim, +6 authors, M Clemons.
Curr Oncol, 2015 Feb 17; 22(1). PMID: 25684986    Free PMC article.
Review.
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
V Petry, D M Gagliato, +8 authors, M S Mano.
Braz J Med Biol Res, 2015 Mar 12; 48(5). PMID: 25760024    Free PMC article.
A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond.
C E Simmons, S Hogeveen, +8 authors, S Gandhi.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848338    Free PMC article.
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Lale Kostakoglu, Fenghai Duan, +13 authors, ACRIN 668 Investigative Team.
J Nucl Med, 2015 Sep 12; 56(11). PMID: 26359256    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Review.
Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
Naoto T Ueno, Eleftherios P Mamounas.
Breast Cancer Res Treat, 2016 Apr 14; 156(3). PMID: 27072366    Free PMC article.
Review.
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Z A Nahleh, W E Barlow, +11 authors, G N Hortobagyi.
Breast Cancer Res Treat, 2016 Jul 10; 158(3). PMID: 27393622    Free PMC article.
Current achievements and future perspectives of metronomic chemotherapy.
Adriana Romiti, Rosa Falcone, Michela Roberto, Paolo Marchetti.
Invest New Drugs, 2016 Dec 03; 35(3). PMID: 27909934
Review.
Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.
Malgorzata Banys-Paluchowski, Eugen Ruckhäberle, +2 authors, Tanja Fehm.
Geburtshilfe Frauenheilkd, 2017 Mar 24; 77(2). PMID: 28331236    Free PMC article.
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.
Audrey Monneur, Anthony Goncalves, +11 authors, François Bertucci.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029489    Free PMC article.
Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
Dawn L Hershman, Cathee Till, +4 authors, Joseph M Unger.
J Clin Oncol, 2018 Mar 28; 36(26). PMID: 29584550    Free PMC article.
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
Naoto T Ueno, Jose Rodrigo Espinosa Fernandez, +19 authors, Wendy A Woodward.
J Cancer, 2018 May 04; 9(8). PMID: 29721054    Free PMC article.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Georgiana K Ellis, William E Barlow, +6 authors, Robert B Livingston.
J Clin Oncol, 2011 Jan 12; 29(8). PMID: 21220618    Free PMC article.
Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.
Richard M Logan, Abdul Rahman Al-Azri, +10 authors, Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).
Support Care Cancer, 2020 Feb 23; 28(5). PMID: 32080767
Systematic Review.
A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients.
Oluwadamilola M Fayanju, Yi Ren, +4 authors, John H Stewart.
JNCI Cancer Spectr, 2020 Mar 27; 4(2). PMID: 32211583    Free PMC article.
Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies.
Terisse A Brocato, Ursa Brown-Glaberman, +10 authors, Vittorio Cristini.
JCI Insight, 2019 Mar 06; 5. PMID: 30835256    Free PMC article.
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
Yuqin Ding, Kaijing Ding, +3 authors, Xiaowen Ding.
PLoS One, 2020 May 30; 15(5). PMID: 32470093    Free PMC article.
Update on systemic treatment for newly diagnosed inflammatory breast cancer.
Sudpreeda Chainitikun, Sadia Saleem, +2 authors, Naoto T Ueno.
J Adv Res, 2021 Apr 13; 29. PMID: 33842000    Free PMC article.
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
Sudpreeda Chainitikun, Jose Rodrigo Espinosa Fernandez, +7 authors, Naoto T Ueno.
PLoS One, 2021 Apr 17; 16(4). PMID: 33861773    Free PMC article.